XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Acquired Intangible Assets, Net

9 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Text Block]

6.	Acquired Intangible Assets, Net

Intangible assets as of September 30, 2024 and December 31, 2023 consisted of the following:

																December 31,
			Nine Months ended September 30, 2024													2023
	Gross Value		Plus: Additions		Less: Accumulated Currency Translation Adjustment			Less: Current Period Impairment Charge			Less: Accumulated Amortization			Net Book Value		Net Book Value		Weighted Average Useful Life
Developed technology	$	33,061	$	600	$	(1,608	)	$	(718	)	$	(29,997	)	$	1,338	$	1,973	$	15
In-process research & development		2,656		-		(1,006	)		-			-			1,650		1,650	Indefinite
Customer relationships		3,887		-		-			(316	)		(3,571	)		-		360		10
Distributor Relationships		4,700		-		(415	)		-			(4,285	)		-		-		5
Patents		1,000		-		(189	)		-			(764	)		47		83		16
Tradenames		4,641		-		-			(126	)		(4,469	)		46		560		5
Total	$	49,945	$	600	$	(3,218	)	$	(1,160	)	$	(43,086	)	$	3,081	$	4,626		12

The aggregate amortization expense related to intangible assets was $0.3 million and $1.9 million for the three-month periods ended September 30, 2024 and 2023, respectively and $1.0 million and $5.8 million for the nine-month periods ended September 30, 2024 and 2023, respectively. During the three-month period ended September 30, 2024, the Company acquired $0.6 million new drug application (“NDA”) that has regulatory approval in the U.S. that it has recorded as developed technology. The Company also recorded a $1.2 million charge to intangible assets related to its Arthrosurface asset group during the three-month period ended September 30, 2024 due to the Company not expecting to recover the value of the intangible asset from the expected net proceeds related to the sale of the Arthrosurface business (see Note 15).

As of September 30, 2024 scheduled amortization of intangible assets is as follows:

Remainder of 2024	$	252
2025		347
2026		232
2027		182
2028		32
Thereafter		386
Total	$	1,431